Aripiprazole augmentation induced hypertension in major depressive disorder: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 305-306

  Hsiao, Yi Ling ^a   Chen, Shaw Ji ^a,b   Shen, Tsu Wang ^b   Chang, Chun Hung ^a   Chen, Shao Tsu ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DULOXETINE; HEMOGLOBIN A1C; INSULIN LISPRO; NIFEDIPINE; RAMIPRIL;

ADULT; CASE REPORT; CHRONIC KIDNEY FAILURE; DECREASED APPETITE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAMILTON SCALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSOMNIA; LETTER; MAJOR DEPRESSION; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PSYCHOMOTOR RETARDATION; PSYCHOSOCIAL WITHDRAWAL; SUICIDE ATTEMPT; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; PIPERAZINES; QUINOLONES; THIOPHENES;

EID: 78650956776     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.024     Document Type: Letter

References (10)

1. Bauer M., Pretorius H.W., Constant E.L., Earley W.R., Szamosi J., Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009, 70:540-549.
2. Borras L., Constant E.L., Eytan A., Huguelet P. Hypertension and aripiprazole. Am J Psychiatry 2005, 162:2392.
3. Greden J.F. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001, 62(Suppl 16):26-31.
4. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
5. Meyer M.C., Baldessarini R.J., Goff D.C., Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 1996, 15:333-346.
6. Pitchot W., Ansseau M. Aripiprazole, hypertension, and confusion. J Neuropsychiatry Clin Neurosci 2010, 22(123):E33.
7. Skinner M.H., Kuan H.Y., Pan A., Sathirakul K., Knadler M.P., Gonzales C.R., et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003, 73:170-177.
8. Thase M.E., Trivedi M.H., Nelson J.C., Fava M., Swanink R., Tran Q.V., et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. prim. care companion. J Clin Psychiatry 2008, 10:440-447.
9. Trivedi M.H., Thase M.E., Osuntokun O., Henley D.B., Case M., Watson S.B., et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009, 70:387-396.
10. Waade R.B., Christensen H., Rudberg I., Refsum H., Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009, 31:233-238.